Prestige BioPharma Limited (KRX:950210)
South Korea
· Delayed Price · Currency is KRW 9,020.00
-40.00 (-0.44%)
Last updated: Apr 29, 2026, 1:50 PM KST
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 108.89 billion as of April 29, 2026. Its market cap has decreased by -31.98% in one year.
Market Cap
108.89B
Enterprise Value
197.93B
Revenue
19.02B
Ranking
n/a
PE Ratio
39.84
Stock Price
9,020.00
Market Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 108.89B, a decrease of -69.80%. That is a compound annual growth rate of -21.60%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 28, 2026 | 108.89B | -29.49% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Oncocross | 107.32B |
| IMB Dx | 102.61B |
| iNtRON Biotechnology | 120.13B |
| CG Invites | 98.96B |
| Amicogen | 131.18B |
| GeneOne Life Science | 91.67B |
| ENCell | 176.61B |
| Vaxcell-Bio Therapeutics | 181.17B |